Meeting
2016 ASCO Annual Meeting
Influence of melanocortin-1 receptor (MC1R) polymorphisms on clinical outcomes of patients with metastatic melanoma harboring the BRAF mutation and treated with BRAF inhibitors.
Authors
Sabino Strippoli
Medical Oncology Department, National Cancer Research Center, “Giovanni Paolo II”, Bari, Italy
Sabino Strippoli , Gabriella Guida , Anna Ferretta , Nicola Bartolomeo , Amalia Azzariti , Stefania Tommasi , Claudia Grieco , Anna Albano , Stefania Guida , Vito Lorusso , Michele Guida
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9574)
DOI
10.1200/JCO.2016.34.15_suppl.9574
Abstract #
9574
Poster Bd #
179
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).
First Author: Matthew Dankner
Poster
2023 ASCO Annual Meeting
A powerful drug combination strategy targeting BRAF-mutant melanoma.
First Author: Luke Daniel Rothermel
Poster
2020 ASCO Virtual Scientific Program
The impact of BRAF mutation status on clinical outcomes with single-agent PD-1 inhibitor versus combination ipilimumab/nivolumab.
First Author: Vincent The-Luc Ma
Poster
2016 ASCO Annual Meeting
Phase I study of vemurafenib and heat shock protein 90 (HSP90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma.
First Author: Zeynep Eroglu